Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4 Multicenter, Randomized, Double-Blind Study of Risankizumab for the Treatment of Adult Subjects With Moderate to Severe Genital Psoriasis or Moderate to Severe Scalp Psoriasis

NCT05969223 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05969223
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05969223 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4 Multicenter, Randomized, Double-Blind Study of Risankizumab for the Treatment of Adult Subjects With Moderate to Severe Genital Psoriasis or Moderate to Severe Scalp Psoriasis
Lead sponsor
AbbVie
Phase
Phase 4
Overall status
Completed
Start date
August 10, 2023
Completion date
November 28, 2025
Enrollment
214 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

genital psoriasis, scalp psoriasis